Mosaic chromosome 20q deletions are more frequent in the aging population.

Deletions on the long-arm of chromosome 20, del(20q), are common karyotypic abnormalities in myeloid disorders. Bioinformatic analyses of the B-allele frequency and log R ratio values from genome-wide association data have identified individuals who are mosaic for large structural abnormalities (>2 Mb). We investigated the most common autosomal event, namely mosaic del(20q), in 46 254 nonhematologic cancer cases and 36 229 cancer-free controls. We detected 91 mosaic del(20q) in leukocytes (80%) and buccal material (20%). The mosaic del(20q) mapped to a well-characterized minimally deleted region (MDR) reported in myeloid disorders. Common breakpoint clusters map to the coordinates of 29.9 to 31.5 Mb on the centromeric side of mosaic del(20q), and 42.0 to 45.4 Mb and 48.1 to 50.7 Mb on the telomeric end (GRCh36). Multivariate analyses suggest del(20q) increases with age, and is more common in males but less common in individuals of African ancestry. No conclusive associations were noted between the presence of mosaic del(20q) and subsequent solid tumor risk. Our observations demonstrate that the MDR of del(20q) is the most common large scale mosaic autosomal abnormality in whole blood and has a frequency of ∼1 in every 1000 adults over the age of 50, which exceeds the expected incidence of myeloid leukemia in the population. Our results indicate that subclonal mosaic events of a region implicated in myeloid disorders on 20q are more frequent than the predicted population-estimated incidence of myeloid diseases, and thus suggest that these events can be tolerated until additional events accumulate that drive myeloid disorders.

[1]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  T. S. Wan Cancer Cytogenetics , 2017, Methods in Molecular Biology.

[3]  William Wheeler,et al.  Characterization of large structural genetic mosaicism in human autosomes. , 2015, American journal of human genetics.

[4]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[5]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[6]  Stephen J Chanock,et al.  Detectable clonal mosaicism in the human genome. , 2013, Seminars in hematology.

[7]  Kirsten R. McEwen,et al.  Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions , 2013, Clinical Epigenetics.

[8]  C. Stiller,et al.  Incidence, survival and prevalence of myeloid malignancies in Europe. , 2012, European journal of cancer.

[9]  William Wheeler,et al.  Detectable clonal mosaicism and its relationship to aging and cancer , 2012, Nature Genetics.

[10]  Ingo Ruczinski,et al.  Detectable clonal mosaicism from birth to old age and its relationship to cancer , 2012, Nature Genetics.

[11]  M. Hirai,et al.  Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. , 2012, Cancer genetics.

[12]  A. Stamatoullas,et al.  Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. , 2011, Leukemia research.

[13]  A. Jankowska,et al.  Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.

[14]  Juan R. González,et al.  R-Gada: a fast and flexible pipeline for copy number analysis in association studies , 2010, BMC Bioinformatics.

[15]  P. D. Dal Cin,et al.  Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura , 2009, British journal of haematology.

[16]  Valeria Nofrini,et al.  Totipotent stem cells bearing del(20q) maintain multipotential differentiation in Shwachman Diamond syndrome , 2009, British journal of haematology.

[17]  Kai Wang,et al.  Copy Number Variation Detection via High-Density SNP Genotyping. , 2008, CSH protocols.

[18]  Ronald A. DePinho,et al.  How stem cells age and why this makes us grow old , 2007, Nature Reviews Molecular Cell Biology.

[19]  K. Ohyashiki,et al.  Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. , 2006, Cancer genetics and cytogenetics.

[20]  P. Deloukas,et al.  Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies , 2004, British journal of haematology.

[21]  S. E. Jacobsen,et al.  MDS/AML‐associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q) , 2004, Genes, chromosomes & cancer.

[22]  A. Green,et al.  Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Steensma,et al.  Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? , 2003, Leukemia research.

[24]  D. Gudbjartsson,et al.  A high-resolution recombination map of the human genome , 2002, Nature Genetics.

[25]  Hartmut Geiger,et al.  The aging of lympho-hematopoietic stem cells , 2002, Nature Immunology.

[26]  Pardis C Sabeti,et al.  Linkage disequilibrium in the human genome , 2001, Nature.

[27]  T. L. Hood,et al.  Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes , 2000, Oncogene.

[28]  P. Wang,et al.  Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. , 2000, Genomics.

[29]  C. Mecucci,et al.  Cytogenetics of myelodysplastic syndromes. , 1999, Forum.

[30]  A. Green,et al.  Molecular genetics and cytogenetics of myeloproliferative disorders. , 1998, Bailliere's clinical haematology.

[31]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[32]  G. Dewald,et al.  Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. , 1996, American journal of clinical pathology.

[33]  P. Morel,et al.  Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.

[34]  G. Dewald,et al.  Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms. , 1993, Cancer genetics and cytogenetics.

[35]  F. Mitelman,et al.  Cytogenetic analysis in the diagnosis of acute leukemia , 1992, Cancer.